LundMay 7, 2014

Shalini Andersson, CVMD Mikael Varga, RIAPer-Erik Strömstedt, Discovery SciencesMagnus Klarqvist, RIA

AstraZeneca R&D Mölndal

Our commitment to making a meaningful difference in healthcare is founded on our innovative science. The pursuit of scientific excellence that addresses unmet patient need guides everything we do.

Pascal SoriotCEO

Mission: To push the boundaries of science to deliver life-changing medicines

Om AstraZeneca

With three strategic priorities

AchieveScientific Leadership

Be a great place to work

Return to growth

1 2 3

Our strategy is focused on innovation

Increase proximity to bioscience clusters and co-locate around three strategic sites

4

Proximity to NIH, Johns Hopkins New site in Cambridge with close proximity

to University of Cambridge and world class UK bioscience community

Connections to Karolinska Institute & Medicon Valley

Gaithersburg MölndalCambridge

Leverage historical strength Respiratory and CV/Met

Co-locate around biologics/specialty care

Co-locate R&D in world-class science cluster

Our research and developmentTo deliver the next generation

Biologics Small Molecules

Immuno - therapies

Protein engineering

NeuroscienceInfection

& Vaccines

CV- Metabolism

Respiratory, Inflammation

& AutoimmunityOncology

Core Therapy Areas Opportunity-focused

• Two iMeds - RIA and CVMD• Safety and Discovery Sciences• A large Development organisation• Several centers of excellence, eg inhalation technologies and transgenics• Proximity to academic centers and Europes largest hospital

AstraZeneca R&D Mölndal

A strong heritage to build on

6

2,300 dedicated colleagues in Mölndal...

901 in Research – 2 iMeds 1,004 in Development - GMD 60 % women

40 % men

1,570 have an academic degree 570 have a PhD >30 professorers >30 post-docs

…including >250 scientists from 30 countries who bring new insights, expertise and energy!

Our current focus in RIA

• Respiratory, Inflammation & Autoimmunity (RIA) Asthma COPD (Chronic obstructive pulmonary disease) Idiopathic Pulmonary Fibrosis Rheumatology Autoimmune disorders

COPD

10

AZ has a strong and continuing presence in front line COPD care based on bronchodilator/anti-inflammatory therapy

What’s next?

Hallmarks of COPDCOPD is mixed disease with both airway obstructions and loss of functional lung

Breathlessness in COPD is more than airflow obstruction

Our current focus in CVMD

• Cardiovascular and Metabolic diseases (CVMD) Diabetic Nephropathy Cardiac Regeneration Islet Health and Metabolism

Cardiac Regeneration

Diabetic Nephropathy

Islet Cell Health (Diabetes)

Cardiac Regeneration

Goal To identify and develop small or large molecules that enhance endogenous regenerative capacity of the heart for the treatment of post-MI cardiac dysfunction and heart failure. VisionTo launch a new therapy which will offer an entirely new treatment paradigm for patients who are dying of heart failure today.

Induction of proliferation of existing cardiomyocytes

Direct reprogramming of cardiac fibroblasts into cardiomyocytes or cardiac progenitors

Activation of resident cardiac progenitor cells in the heart: Epicardial progenitor cells (EPDC) or cardiac stem cells (CSC)

Discovery Sciences

14 Per-Erik Strömstedt | May 7, 2014 | Discovery Sciences

• Compound management

• Biobanks

(clinical samples)

• Hit generation

• SAR screening

• Ion channel centre

of excellence

• Crystallography; first structures,

iterative structures

• NMR and other biophysical

techniques

• Fragment Chemistry

• Chemical Biology

• Computational biology

• Cheminformatics

• Predictive Chemistry

• Compound collection enhancement

• Proteins

• Cells

• Transgenics

• Antibodies

DS

• Project support

• Statistical qualification

Discovery Sciences (DS) provides centralised, state-of-the art support for hit finding, lead optimization and target validation for all therapeutic research areas with AZ.

• Assay development

• High content biology assays

Partnering, collaborations and open innovation remain key to pushing the boundaries of science

We are driving science through collaborations…

…more than 90 partnerships in the last three years

To deliver the next generation of medicines we must continue to find ways to combine our science with the best science that’s happening elsewhere

Challenging ourselves to find new ways to break through the barriers and work more openly with scientists in other organisations who share our passion for patients and who can bring different perspectives to innovative research

Accessible through an Open Innovation Website

http://openinnovation.astrazeneca.com

• Summerworker• Master’s thesis• Graduate programme• Post-Doc programme

Opportunities at AZ Mölndal

21 Author | 00 Month Year Set area descriptor | Sub level 1

60 Summer workers 201322 Master’s thesis students6 Graduate students33 Post-Docs

With the ambition to increase …

AstraZeneca Post-Doc ProgrammeInvesting in innovative science

The next generation of scientific mindsAstraZeneca Post-Doc Programme gives post-doctoral scientists the chanceto undertake high-quality, innovative research in a cross-discipline scientificenvironment within the pharmaceutical industry.

AstraZeneca post-doctoral scientists:• Conduct independent, cutting-edge research in state-of-the-art facilities• Collaborate with AstraZeneca scientists in discovery and drug development teams• Work alongside a world-leading academic advisor• Publish their work in high-quality scientific journals and communicate research findings at international scientific conferences.

Each scientist receives a tailored training and development programme, aligned with the established AstraZeneca approach to personal development. This includes core training on drug discovery and development, as well as on key skills, such as presentation delivery and publication writing.

AstraZeneca Internal Post-doc Program

Post-doc proposal selection based on

• Scientific Novelty

• Feasability (Scientific, Technical and 2 yr time frame)

• Availability of academic collaborator

For more information on the opportunities of the programme, visit:http://www.astrazeneca.com/Research/capabilities/AstraZeneca-expandspostdoc-program

For the latest vacancies, visit:http://www.astrazenecacareers.com/students-all/postdoc-program2/

http://www.candidatecare.com/srccsh/RTI.home?r=2000032721810&c=11&d=astrazeneca.candidatecare.com&_dissimuloSSO=XTZ23XJ29Jg:66k7sC-1j79cH6WaCOhgu4K8OQE

Graduate vacancies for AZ Sweden are now live with a closing date of the 19th May 2013.

Great Place to Work!

AstraZeneca R&D Mölndal

To push the boundaries of science to deliver life-changing medicines

anddiscussion

questions ???

25

To push the boundaries of science to deliver life-changing m

edicines

>20 Clinical readycompounds

>40 Mechanistic tool compounds

up to $100K grants

Potential to partner your molecules

Prizes for solutions to R&D challenges

Partnerships

New clinically validated projects

New lead optimization projects

New targets/hit ID projects

Access to novel molecules

Novel solutions

Clinical Compound Bank

Pharmacology Toolbox

Target Innovation

New Molecule Profiling

R&D Challenges

Suggestion Box Ideas for future partnerships

Academics

Why is it Attractive?

AZGeneration of N

ovel data for publications and advance medical

science

A global business50,000 employees.Research across 3 continents.$4.2 billion invested in R&D in 2013.Manufacturing in 17 countries.Sales in 100 countries.$25.7 billion sales in 2013.

AstraZeneca Mölndal

2 150900

1 100>250

employees

in Innovative Medicines

in Global Medicines

Development colleagues from 30

countries1 614 with academic degree

574 PhDs3